Company: OSE Immunotherapeutics
Job title: Chief Scientific Officer
Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, as project manager and then he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.
Selective Anti-SIRPα Antibody: Next generation Myeloid Checkpoint Inhibitor 12:30 pm
• Looking into OSE’s approach to targeting SIRPA instead of CD47 • Review anti-SIRPa efficacy in monotherapy and combination therapies • Discuss translational research characterizing safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in solid tumorsRead more
day: Day One